Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system: review

Pharmaceutical Biology

Volumn 54, Issue 12, 2016, Pages 3126-3135

  Zaporozhets, Tatyana ^a   Besednova, Natalia ^a  

^a Institute of Epidemiology and Microbiology   (Russian Federation)

Author keywords

Angiogenesis; atherosclerosis; cardiovascular diseases; fucoidan; inflammation; vasculogenesis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT; FATTY ACID BINDING PROTEIN; FREE RADICAL; FUCOIDIN; FUCOIDIN DERIVATIVE; L SELECTIN; MACROPHAGE SCAVENGER RECEPTOR; METALLOPROTEINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYSACCHARIDE SULFATE; SCAVENGER RECEPTOR; THROMBIN; UNCLASSIFIED DRUG; POLYSACCHARIDE; SULFATE;

ANGIOGENESIS; ANTIADHESIVE ACTIVITY; ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BROWN ALGA; CARDIOVASCULAR DISEASE; DRUG FORMULATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; HYPOLIPIDEMIC ACTIVITY; IMMUNOMODULATORY ACTIVITY; NEOINTIMA; NONHUMAN; PROANGIOGENIC ACTIVITY; PROVASCULOGENIC ACTIVITY; REVASCULARIZATION; REVIEW; SMOOTH MUSCLE CELL; ANIMAL; CARDIOVASCULAR SYSTEM; CHEMISTRY; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; PHAEOPHYTA; POLYSACCHARIDES; SULFATES;

EID: 84998636604     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880209.2016.1185444     Document Type: Review

References (128)

1. Ali S, Jenkins Y, Kirkley M, Dagkalis A, Manivannan A, Grane I, Kirby J. 2008. Leukocyte extravasation:an immunoregulatory role for alpha-L-fucosidase? J Immunol. 181:2407–2413.
2. Alkhatib B, Freguin-Bouilland C, Lallemand F, Henry JP, Litzler PY, Marie JP, Richard V, Thuillez C, Plissonnier D. 2006. Low molecular weight fucan prevents transplant coronaropathy in rat cardiac allograft model. Transpl Immunol. 16:14–19.
3. Asahara N, Isner JM. 2002. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res. 11:171–178.
4. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964–967.
5. Bachelet L, Bertholon I, Lavigne D, Vassy R, Jandrot-Perrus M, Chaubet F, Letourneur D. 2009. Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. Biochim Biophys Acta. 1790:41–46.
6. Badoff C, Dimmeler S. 2006. Neovascularization and cardiac repair by bone marrow-derived stem cells. Handb Exp Pharmacol. 174:283–298.
7. Barrabés JA, Garcia-Dorado D, Mirabet M, Inserte J, Agulló L, Soriano B, Massaguer A, Padilla F, Lidón RM, Soler-Soler J. 2005. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol. 45:293–299.
8. Barahona T, Chandia NP, Encinas MV, Matsuhiro B, Zúñiga E. 2011. Antioxidant capacity of sulfated polysaccharides from seaweeds. A kinetic approach. Food Hydrocolloids. 25:529–535.
9. Berteau O, Mulloy B. 2003. Sulfated fucans, fresh perspectives:structures, functions, and biological priperties of sulfated fucans and overview of enzymes active toward this class of polysaccharide. Glycobiology. 13:29–40.
10. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. 2002. Innate and acquired immunity in atherogenesis. Nat Med. 8:1218–1226.
11. Blondin C, Fisher E, Boisson-Vidal C, Kazatchkine M, Jozefonvicz J, 1994. Inhibition of complement activation by natural sulphated polysaccharides (fucans) from brown seaweed. Mol Immunol. 31:247–253.
12. Boisson-Vidal C, Chaubet F, Chevolot L, Sinquin C, Theveniaux J, Millet J, Sternberg C, Mulloy B, Fischer AM. 2000. Relationship between antithrombotic activities of fucans and their structure. Drug Develop Res. 51:216–224.
13. Boisson-Vidal C, Zemani F, Caligiuri G, Galy-Fauroux I, Colliec-Jouault S, Helley D, Fischer AM. 2007. Neoangiogenesis induced by progenitor endothelial cells:effect of fucoidan from marine algae. Cardiovasc Hematol Agent Med Chem. 5:67–77.
14. Camara RB, Costa LS, Fidelis GP, Nobre LT, Dantas-Santos N, Cordiro SL, Costa MS, Alves LG, Rocha HA, 2011. Heterofucans from the brown seaweed Canistrocarpus cervicornis with anticoagulant and antioxidant activities. Mar Drugs. 24:124–138.
15. Casu B, Naggi A, Torri G. 2010. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 29:442–452.
16. Chabut D, Fischer AM, Colliec-Jouault S, Laurendeau I, Matou S, Le Bonniec B, Helley D. 2003. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression. Mol Pharmacol. 64:696–702.
17. Chabut D, Fischer AM, Helley D, Colliec S. 2004. Low molecular weight fucoidan promotes FGF-2-induced vascular tube formation by human endothelial cells, with decreased PAI-1 release and ICAM-1 downregulation. Thromb Res. 113:93–95.
18. Chen AF, Chen DD, Daiber A, Faraci FM, Li H, Rembold CM, Laher I. 2012. Free radical biology of the cardiovascular system. Clin Sci. 123:73–91.
19. Chen D, Wu XZ, Wen ZY. 2008. Sulfated polysaccharides and immune response:promoter or inhibitor? Panminerva Med. 50:177–183.
20. Clément MJ, Tissot B, Chevolot L, Adjadj E, Du Y, Curmi PA, Daniel R. 2010. NMR characterization and molecular modeling of fucoidan showing the importance of oligosaccharide branching in its anticomplementary activity. Glycobiology. 20:883–894.
21. Cuong HD, Thuy TT, Huong TT, Ly BM, Van TT. 2015. Structure and hypolipidaemic activity of fucoidan extracted from brown seaweed Sargassum henslowianum. Nat Prod Res. 29:411–415.
22. Cumashi A, Ushakova NA, Preobrazhenskaya ME, D'Incecco A, Piccoli A, Totani L, Tinari N, Morozevich GE, Berman AE, Bilan MI, et al. 2007. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 17:541–552.
23. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX. 2005. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis. 178:9–17.
24. Daugherty A, Rateri DL, Whitman SC. 2000. Class A scavenger receptors:Recent advances in elucidation of structure-function relationships and their role in atherosclerosis. Curr Opin Cardiovascular Pulm Ren Invest Drugs. 2:223–232.
25. Davignon J, Ganz P. 2004. Role of endothelial dysfunction in atherosclerosis. Circulation. 109:III-27–I32.
26. Deux JF, Meddahi-Pellé A, Le Blanche AF, Feldman LJ, Colliec-Jouault S, Brée F, Boudghène F, Michel JB, Letourneur D. 2002. Low molecular weight fucoidan prevents neointimal hyperplasia in rabbit iliac artery in-stent restenosis model. Arterioscler Thromb Vasc Biol. 22:1604–1609.
27. Do H, Pyo S, Sohn EH. 2010. Suppression of iNOS expression by fucoidan is mediated by regulation of p38 MAPK, JAK/STAT, AP-1 and IRF-1, and depends on up-regulation of scavenger receptor B1 expression in TNF-alpha- and IFN-gamma-stimulated C6 glioma cells. J Nutr Biochem. 21:671–679.
28. Drozd NN, Miftahova NT, Savchik E, Kalinina TB, Makarov VA, Imbs TI, Zviagintseva TN, Kuznetsova TA, Besednova NN. 2011. Antithrombotic and hemorrhagic activities of fucoidan isolated from Fucus evanescens brown algae. Exp Clin Pharm. 74:26–30.
29. Du X, Jiang S, Liu H, Xin X, Li J, Geng M, Jiang H. 2010. MS80, a novel sulfated polysaccharide, inhibits CD40-NF-kappaB pathway via targeting RIP2. Mol Cell Biochem. 337:277–285.
30. Durand E, Helley D, Al Haj Zen A, Dujols C, Bruneval P, Colliec-Jouault S, Fischer AM, Lafont A. 2008. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis. J Vasc Res. 45:529–537.
31. Dushkin MI. 2006. Macrophages and atherosclerosis:pathophysiological and therapeutic aspects. Bul SB RAMS. 2:47–55.
32. Fearon IM, Faux SP. 2009. Oxidative stress and cardiovascular disease:Novel tools give (free) radical insight. J Mol Cell Cardiol 47:372–381.
33. Fitton JH. 2011. Therapies from fucoidan; multifunctional marine polymers. Mar Drugs. 9:1731–1760.
34. Fonseca RJ, Santos GR, Mourao PA. 2009. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications. Thromb Haemost. 102:829–836.
35. Freedman SB, Isner JM. 2002. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 136:54–71.
36. Fréguin-Bouilland C, Alkhatib B, David N, Lallemand F, Henry JP, Godin M, Thuillez C, Plissonnier D. 2007. Low molecular weight fucoidan prevents neointimal hyperplasia after aortic allografting. Transplantation. 83:1234–1241.
37. Frenette PS, Weiss L. 2000. Sulfated glycans induce rapid hematopoietic progenitor cell mobilization:evidence for selectin-dependent and independent mechanisms. Blood. 96:2460–2468.
38. Goldman O, Feraud O, Boyer-Di Ponio J, Driancourt C, Clay D, Le Bousse-Kerdiles MC, Bennaceur-Griscelli A, Uzan G. 2009. A boost of BMP4 accelerates the commitment of human embryonic stem cells to the endothelial lineage. Stem Cells. 27:1750–1759.
39. Gustafson B. 2010. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Tromb. 17:1–10.
40. Habets KL, van Puijvelde GH, van Duivenvoorde LM, van Wanrooij EJ, de Vos P, Tervaert JW, van Berkel TJ, Toes RE, Kuiper J. 2010. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res. 85:622–630.
41. Hansson GK, Libby P. 2006. The immune response in atherosclerosis:a double-edged sword. Nat Rev Immunol. 6:508–519.
42. Heinzelmann M, Polk HC, Miller FN. 1998. Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan. Infect Immun. 66:5842–5847.
43. Hlawaty H, Suffee N, Sutton A, Oudar O, Haddad O, Ollivier V, Laguillier-Morizot C, Gattegno L, Letourneur D, Charnaux N. 2011. Low molecular weight fucoidan prevents intimal hyperplasia in rat injured thoracic aorta through the modulation of matrix metalloproteinase-2 expression. Biochem Pharmacol. 81:233–243.
44. Hu JL, Van den Steen PE, Sang QX, Opdenakker G. 2007. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 6:480–498.
45. Hwang PA, Chien SY, Chan YL, Lu MK, Wu CH, Kong ZL, Wu CJ. 2011. Inhibition of lipopolysaccharide (LPS)-induced inflammatory responses by Sargassum hemiphyllum sulfated polysaccharide extract in RAW 264.7 macrophage cells. J Agric Food Chem. 59:2062–2068.
46. Iesaki T, Takeuchi M, Okano M, Hashimoto R, Kakigi R, Ishii Y, Okada T. 2014. Fucoidan, a ligand of scavenger receptor class a, causes vascular relaxation through a nitric oxide/cGMP-mediated pathway in rat aorta. Atherosclerosis. 235:e36.
47. Imbs TI, Skriptsova AV, Zvyagintseva TN. 2015. Antioxidant activity jf fucose-containing sulfated polysaccharides obtained from Fucus evanescens by different extraction methods. J Appl Phycol. 27:545–553.
48. Jameel A, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL. 2013. Statin modulation of human T-cell proliferation, IL-1β and IL-17 production, and IFN- γ T cell expression:synergy with conventional immunosuppressive agents. Int J Inflam. 2013:434586.
49. Jones CB, Sane DC, Herrington DM. 2003. Matrix metalloproteinases:a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 59:812–823.
50. Kim BS, Park JY, Kang HJ, Kim HJ, Lee J. 2014. Fucoidan/FGF-2 induces angiogenesis through JNK- and p38-mediated activation of AKT/MMP-2 signalling. Biochem Biophys Res Commun. 450:1333–1338.
51. Kim KJ, Lee OH, Lee BJ. 2010. Fucoidan, a sulfated polysaccharide, inhibits adipogenesis through the mitogen-activated protein kinase pathway in 3T3-L1 preadipocytes. Life Sci. 86:791–797.
52. Kim JM, Bae IH, Lim KS, Park JK, Park DS, Lee SY, Jang EJ, Ji MS, Sim DS, Hong YJ, et al. 2015. A method for coating fucoidan onto bare metal stent and in vivo evaluation. Prog Org Coat. 78:348–356.
53. Kim MJ, Chang UJ, Lee JS. 2009. Inhibitory effects of fucoidan in 3T3-L1 adipocyte differentiation. Mar Biotechnol. 11:557–562.
54. Kozlov VA, Dushkin MI, Vereshchagin EI. 2008. Vaccines against atherosclerosis:the state of the problem and perspectives. Cytokines Inflam. 7:8–14.
55. Krylov VB, Ustyuzhanina NE, Nifant'ev N. 2011. Synthesis of low molecular weight carbohydrate mimics heparin. Bioorg Chem. 37:745–779.
56. Lakhtin MV, Karaulov AV, Lakhtin VM, Alyoshkin VA, Afanasyev SS, Nesvizskyi UV, Afanasyev MS, Vorapaeva EA, Alyoshkin AV. 2012. Lectin-glycoconjugate system in humans organism. Immunopathol Allergol Infect. 1:27–36.
57. Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D. 2006. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem. 281:37844–37852.
58. Lee JH, Lee SH, Choi SH, Asahara T, Kwon SM. 2015. The sulfated polysaccharide fucoidan rescues senescence of endothelial colony-forming cells for ischemic repair. Stem Cells. 33:1939–1951.
59. Lee NY, Ermakova SP, Zvyagintseva TN, Kang KW, Dong Z, Choi H. 2008. Inhibitory effects of fucoidan on activation of epidermal growth factor receptor and cell transformation in JB6 Cl41 cells. Food Chem Toxicol. 46:1793–1800.
60. Lee WW, Ahn G, Arachchillage JP, Kim YM, Kim SK, Lee BJ, Jeon YJ. 2011. A polysaccharide isolated from Ecklonia cava fermented by Lactobacillus brevis inhibits the, inflammatory response by suppressing the activation of nuclear factor-κB in lipopolysaccharide-induced RAW 264.7 macrophages. J Med Food. 14:1546–1553.
61. Leeper NJ, Hunter AL, Cooke JP. 2010. Stem cell therapy for vascular regeneration:adult, embryonic, and induced pluripotent stem cells. Circulation. 122:517–526.
62. Li C, Gao Y, Xing Y, et al. 2011. Fucoidan, a sulfated polysaccharide from brown algae, against myocardial ischemia-reperfusion injury in rats via regulating the inflammation response. Food Chem Toxicol. 49:2090–2095.
63. Linhardt R, Toida T. 2004. Role of glycosaminoglycans in cellular communication. Acc Chem Res. 37:431–438.
64. Li C, Gao Y, Xing Y, Zhu H, Shen J, Tian J. 2012. Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells. Phytomedicine. 19:797–803.
65. Liu XL, Liu DY, Wang YQ, Yang LL, Yang X, Wu R, Zou X. 2010. Immunomodulation and antitumor activity of fucoidan from Undaria pinnatifida in vitro. Chinese J Microecol. 22:1074–1076.
66. Lowe JB. 2002. Glycosyltransferases and glycan structures contributing to the adhesive activities of L-, E- and P-selectin counter-receptors. Biochem Soc Symp. 69:33–45.
67. Luyt CE, Meddahi-Pellé A, Ho-Tin-Noe B, Colliec-Jouault S, Guezennec J, Louedec L, Prats H, Jacob MP, Osborne-Pellegrin M, Letourneur D, et al. 2003. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. Pharmacol Exp Ther. 305:24–30.
68. Madeddu P. 2005. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol. 90:315–326.
69. Manzo-Silberman S, Louedec L, Meilhac O, Letourneur D, Michel JB, Elmadbouh I. 2011. Therapeutic potential of fucoidan in myocardial ischemia. J Cardiovasc Pharmacol. 58:626–632.
70. Marinval N, Saboural P, Haddad O, Maire M, Letourner D, Charnaux N, Hlawaty H. 2015. 0024:Angiogenesis potentialized by highly sulfated fucoidan:role of the chemokines and the proteoglycans. Arch Cardiovasc Diss Suppl. 7:148.
71. Marques CT, de Azevedo TCG, Nascimento MS, Medeiros V, Alves L, Benevides N, Rocha H, Leite E. 2012. Sulfated fucans extracted from algae Padina gymnospora have anti-inflammatory effect. Rev Bras Farmacogn. 22:115–122.
72. Massaro M, Scoditti E, Carluccio MA, De Caterina R. 2010. Nutraceuticals and prevention of atherosclerosis:focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. Cardiovasc Ther. 28:e13–e19.
73. Matou S, Helley D, Chabut D, Fischer AM. 2002. Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro. Thromb Res. 106:213–221.
74. Matsubara K, Xue C, Zhao X, Mori M, Sugawara T, Hirata T. 2005. Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells. Int J Mol Med. 15:695–699.
75. Medeiros VP, Queiros KS, Cardoso ML, Monteiro GR, Oliveira FW, Chavante SF, Guimaraes LA, Rocha HA, Leite EL. 2008. Sulfated galactofucan from Lobophora variegata:anticoagulant and anti-inflammatory properties. Biochemistry Mosc. 73:1018–1024.
76. Mourao PAS. 2004. Use of sulfated fucans as anticoagulant and antithrombotic agents:future perspectives. Currt Pharm Des. 10:967–981.
77. Nakamura S, Nambu M, Ishizuka T, et al. 2008. Effect of controlled release of fibroblast growth factor-2 from chitosan/fucoidan micro complex-hydrogel on in vitro and in vivo vascularization. J Biomed Mater Res A. 85:619–627.
78. Nishino T, Nagumo T. 1991. The sulfate-content dependence of the anticoagulant activity of a fucan sulfate from the brown seaweed Ecklonia kurome. Carbohydr Res. 214:193–197.
79. Omata M, Matsui N, Inomata N, Hattori H, Kanatani Y, Takase B, Kishimoto S, Amano Y, Aoki H, Kiyosawa T, et al. 1997. Protective effects polysaccharide fucoidin on myocardial ischemia-reperfusion injury in rats. J Cardiovasc Pharmacol. 30:717–724.
80. Oomizu S, Yanase Y, Suzuki H, Kameyoshi Y, Hide M. 2006. Fucoidan prevents C epsilon germline transcription and NFkappaB p52 translocation for IgE production in B cells. Biochem Biophys Res Commun. 350:501–507.
81. Otrocka ZK, Mahfouzb RR, Makarema JA, Shamseddine AI. 2007. Understanding the biology of angiogenesis:review of the most important molecular mechanisms. Blood Cells Mol Dis. 39:212–220.
82. Park HY, Han MH, Park C, Jin CY, Kim GY, Choi IW, Kim ND, Nam TJ, Kwon TK, Choi YH. 2011. Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in lipopolysaccharide-induced BV2 microglia cells. Food Chem Toxicol. 49:1745–1752.
83. Park MK, Jung U, Roh C. 2011. Fucoidan from marine brown algae inhibits lipid accumulation. Mar Drugs. 9:1359–1367.
84. Patel MK, Mulloy B, Gallagher KL, O'Brien L, Hughes AD. 2002. The antimitogenic action of the sulphated polysaccharide fucoidan differs from heparin in human vascular smooth muscle cells. Thromb Haemost. 87:149–154.
85. Peplow F. 2014. Growth factor- and cytokine-stimulated endothelial progenitor cells in post-ischemic cerebral neovascularization. Neural Regen Re. 9:1425–1429.
86. Pomin VH. 2015. Sulfated glycans in inflammation. Eur J Med Chem. 92:353–369.
87. Pfeilschifter J. 2002. Nitric oxide triggers the expression of proin-flammatory and protective gene products in mesangial cells and the inflamed glomerulus. Nephrol Dial Transplant. 17:347–348.
88. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. 2005. Glycomics:an integrated systems approach to structure-function relationships of glycans. Nature Methods. 2:817–824.
89. Religa P, Kazi M, Thyberg J, Gaciong Z, Swedenborg J, Hedin U. 2000. Fucoidan inhibits smooth muscle cell proliferation and reduces mitogen-activated protein kinase activity. Eur J Vasc Endovasc Surg. 20:419–426.
90. Rouzet F, Bachelet-Violette L, Alsac JM, Suzuki M, Meulemans A, Louedec L, Petiet A, Jandrot-Perrus M, Chaubet F, Michel JB, et al. 2011. Radiolabeled fucoidan as a P-selectin targeting agent for in vivo imaging of platelet-rich thrombus and endothelial activation. J Nucl Med. 52:1433–1440.
91. Roux N, Brakenhielm E, Freguin-Bouillant C, Lallemand F, Henry JP, Boyer O, Thuillez C, Plissonnier D. 2012. Progenitor cell mobilizing treatments prevent experimental transplant arteriosclerosis. J Surg Res. 176:657–665.
92. Samson S, Mundkur L, Kakkar VV. 2012. Immune response to lipoproteins in atherosclerosis. Cholesterol. 2012:571846
93. Sarlon G, Zemani F, David L, Duong Van Huyen JP, Dizier B, Grelac F, Colliec-Jouault S, Galy-Fauroux I, Bruneval P, Fischer AM, et al. 2012. Therapeutic effect of fucoidan-stimulated endothelial colony-forming cells in peripheral ischemia. J Thromb Haemost. 10:38–48.
94. Shah PK, Chyu KY, Fredrikson GN, Nilsson J. 2005. Immunomodulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiovasc Med. 2:639–646.
95. Shanmugam M, Mody K, 2000. Heparinoid–active suphated polysaccharides from marine algae as potential blood anticoagulant agents. Curr Sci. 79:1672–1683.
96. Sheng GJ, Oh YI, Chang SK, Hsieh-Wilson LC. 2013. Tunable heparan sulfate mimetics for modulating chemokine activity. J Am Chem Soc. 135:10898–10901.
97. Shriver Z, Raguram S, Sasisekharan R. 2004. Glycomics:a pathway to a class of new and improved therapeutics. Nat Rev Drug Discov. 3:863–873.
98. Simonis D, Fritzsche J, Alban S, Bendas G. 2007. Kinetic analysis of heparin and glucan sulfates binding to P-Selectin and its impact on the general understanding of selectin inhibition. Biochemistry. 46:6156–6164.
99. Simons M, Ware JA. 2003. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov. 2:863–872.
100. Siqueira RCL, da Silva MSC, de Alencar DB, Pires Ade F, de Alencar NM, Pereira MG, Cavada BS, Sampaio AH, Farias WR, Assreuy AM. 2011. In vivo anti-inflammatory effect of a sulfated polysaccharide isolated from the marine brown algae Lobophora variegata. Pharm Biol. 49:167–174.
101. Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T. 2002. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice:involvement in mobilization of stem/progenitor cells. Blood. 99:44–51.
102. Sweeney EA, Lortat-Jacob H, Priestley GV, Collins RG, Beaudet AL, Papayannopoulou T. 2000. Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci USA. 97:6544–6549.
103. Tanaka K, Ito M, Kodama M, Tomita M, Kimura S, Hoyano M, Mitsuma W, Hirono S, Hanawa H, Aizawa Y. 2011. Sulfated polysaccharide fucoidan ameliorates experimental autoimmune myocarditis in rats. J Cardvasc Pharmcol Ther. 16:79–86.
104. Tariq A, Athar M, Ara J, Sultana V, Ehteshamul-Haque S, Ahmad M. 2015. Biochemical evaluation of antioxidant activity in extract and polysaccharides fractions in seaweeds. Global J Environ Sci Manage. 1:46–62.
105. Thomas NV, Kim SK. 2014. Fucoidans from marine algae as potential matrix metalloproteinase inhibitors. Adv Food Nutr Res. 72:177–193.
106. Tissot B, Daniel R. 2003. Biological properties of sulfated fucans:the potent inhibiting activity of algal fucoidan against the human compliment system. Glycobiology. 13:29G–30G.
107. Tissot B, Montdargent B, Chevolot L, Varenne A, Descroix S, Gareil P, Daniel R. 2003. Interaction of fucoidan with the proteins of the complement classical pathway. Biochim Biophys Acta. 1651:5–16.
108. Turnbull J, Powell A, Guimond S. 2001. Heparan sulfate:decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 11:75–82.
109. Ustyuzhanina NE, Ushakova NA, Zyuzina KA, Bilan MI, Elizarova AL, Somonova OV, Madzhuga AV, Krylov VB, Preobrazhenskaya ME, Usov AI, et al. 2013. Influence of fucoidans on hemostatic system. Mar Drugs. 11:2444–2458.
110. Ustyuzhanina NE, Bilan MI, Ushakova NA, Usov AI, Kiselevskiy MV, Nifantiev N. 2014. Fucoidans:pro- or antiangiogenic agents? Glycobiology. 24:1265–1274.
111. Vale PR1, Isner JM, Rosenfield K. 2001. Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol. 14:511–528.
112. Venkatesan J, Lowe B, Anil S, Manivasagan P, Kheraif A, Kang KH, Kim SK. 2015. Seaweed polysaccharides and their potential biomedical applications. Starch. 67:381–390.
113. Volpi N. 2006. Therapeutic applications of glycosaminoglycans. Curr Med Chem. 13:1799–1810.
114. Wang YQ, Miao ZH. 2013. Marine-derived angiogenesis inhibitors for cancer therapy. Mar. Mar Drugs. 11:903–933.
115. Wijesinghe W, Jeon Y. 2012. Biological activities and potential industrial applications of fucose rich sulfated polysaccharides and fucoidans isolated from brown seaweeds:a review. Carbohydrate Polymers. 88:13–20.
116. Woollard KJ, Chin-Dusting J. 2007. Therapeutic targeting of P-selectin in atherosclerosis. Inflamm Allergy Drug Targets. 6:69–74.
117. Yuan Y, Macquarrie D. 2015. Microwave assisted extraction of sulfated polysaccharides (fucoidan) from Ascophyllum nodosum and its antioxidant activity. Carbohydrate Polymers 129:101–107.
118. Xueyan F, Changhu X, Yan N, Zhaojie L, Jiachao X. 2004. Acute antihypertensive effects of fucoidan oligosaccharides prepared from Laminaria japonica on renovascular hypertensive rats. J Ocean Univ China (Nat Sci) 34:560–564.
119. Yamomoto K, Nishimura N, Doi T, Imanishi T, Suzuki K, Tanaka T. 1997. The lysine cluster in the collagen-like domain of the scavenger receptor provides for its ligand binding and ligand specificity. FEBS Lett 414:182–184.
120. Yang J, Hirata T, Croce K, Merrill-Skoloff G, Tchernychev B, Williams E, Flaumenhaft R, Furie BC, Furie B. 1999. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med. 190:1769–1782.
121. Yokota T, Nagashima M, Ghazizadeh M, Kawanami O. 2009. Increased effect of fucoidan on lipoprotein lipase secretion in adipocytes. Life Sci 84:523–529.
122. Yogo K, Shimokawa H, Funakoshi H, Kandabashi T, Miyata K, Okamoto S, Egashira K, Huang P, Akaike T, Takeshita A. 2000. Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol. 20:E96–E100.
123. Zhang SM, Xie ZP, Xu ML, Shi LF. 2015a. Cardioprotective effects of fucoidan against hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Pharm Biol. 15:1–6.
124. Zhang W, Oda T, Yu Q, Jin JO. 2015b. Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans. Mar Drugs. 13:1084–1104.
125. Zhang W, Jin W, Sun D, Zhao L, Wang J, Duan D, Zhang Q. 2015c. Structural analysis and anti-complement activity of polysaccharides from Kjellmaniella crsaaifolia. Mar Drugs. 13:1360–1374.
126. Zemani F, Benisvy D, Galy-Fauroux I, Lokajczyk A, Colliec-Jouault S, Uzan G, Fischer AM, Boisson-Vidal C. 2005. Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem Pharmacol. 70:1167–1175.
127. Zen K, Liu Y, Cairo D, Parcos CA. 2002. CD11b/CD18-dependent interactions of neutrophils with intestinal epithelium are mediated by fucosylated proteoglycans. J Immunol. 169:5270–5278.
128. Zvyagintseva T, Shevshenko N, Nazarova I, Scobun AS, Luk'yanov PA, Elyakova LA. 2000. Inhibition of complement activation by water-soluble polysaccharides of some far-eastern brown seaweeds. Comp Biochem Physiol C Toxicol Pharmacol. 126:209–215.